HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

Bristol-Myers Squibb, which manufactures BMS-354825, paid for this study.

AMN107 is effective in patients with Gleevec-resistant ALL and CML

Francis Giles, M.D., professor of medicine in the Department of Leukemia, presented results of the second study, which found that the novel oral targeted therapy, AMN107, can produce responses not only in advanced and Gleevec-resistant CML patients, but also in patients with acute lymphocytic leukemia (ALL) associated with the "Philadelphia chromosome."

The AMN107 Phase I study has accrued 65 patients since opening in May 2004. Even though an optimal dose has yet to be established as no significant toxicities have yet been encountered, more than 50 percent of patients with Gleevec-resistant CML have responded, including cytogenetic and molecular responses in some patients so far, Giles says.

"While more study needs to be done to define a reasonable regimen for this drug, it has, so far, produced very important responses in patients who were desperately ill," he says. "Despite the response rate, we still have not seen any consistent severe side effects, so clearly AMN107 will have a different tolerability profile than Gleevec, a drug which is, in general, very well tolerated," he adds.

"Gleevec changed everything in CML. It has led to marked improvement in survival in all three phases of the disease, and it also has shown benefit in treating the 20 percent of ALL that shares the same genetic abnormality as CML, the Philadelphia chromosome," Giles says. "But a drug that can cope with resistance to Gleevec might do even better across the board, although it must be remembered that we are still learning how to optimally use Gleevec itself, a drug which we have only had available for a few years."

The clinical trial reported by Giles is unusual in that it allows for a rapid "intrapatient" dose escalation. Within the trial, patients are allowed to move to higher doses as they pr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2020)... ... January 23, 2020 , ... MemoryCare.com , a comprehensive ... Best Memory Care Facilities in Pensacola, Florida. The guide identifies 7 memory care ... According to the Alzheimer’s Association , 5.6 million people age 65 and ...
(Date:1/23/2020)... ... 2020 , ... Driving Dynamics Inc., a provider of driver ... North America and around the globe, has announced that, Driving Dynamics Driver Safety ... the company’s website. , Developed for fleet and safety professionals, the publication is ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... agreement with Healthpac, a trusted medical billing software company for revenue cycle ... expanded offering. Healthpac’s customers can now access Relatient's latest solutions to improve ...
(Date:1/23/2020)... ... January 23, 2020 , ... Starting Hearts , a nonprofit ... its first-ever Save More Lives Challenge on Feb. 1, 2020, to align with American ... that can decrease the number one cause of death in the U.S., Sudden Cardiac ...
(Date:1/22/2020)... ... January 22, 2020 , ... ... education services, recently appointed Ilana Glazer as its new external relations director. ... Ilana directs donor relations, grants administration, external communications, community education, brand strategy, ...
Breaking Medicine News(10 mins):
(Date:1/8/2020)... ... January 08, 2020 , ... Preeminent Northern ... Valley, has this week announced the latest medical breakthrough for the spine world, ... a patient. , The newly FDA cleared MiRus Europa™ Pedicle Screw System is ...
(Date:1/8/2020)... ... ... R3 Stem Cell is now offering a Comprehensive Online Stem Cell ... The course is incredibly useful and provides a Certificate of Completion for framing, which ... been the leader for regenerative training with in person workshops. These include Hands On ...
(Date:1/7/2020)... ... 07, 2020 , ... Valencell today announced the ... in hearables and wearables. Valencell will provide the BP sensor system as a ... products. Embedded in an earbud reference design, the technology has demonstrated BP cuff-like ...
Breaking Medicine Technology:
Cached News: